Open an account

Bright Minds Biosciences

DRUG · CANADIAN

$52.48−$0.21 (−0.40%)TodayMarket closed ·
Prev close $52.69

About DRUG

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Employees
0
Headquarters
New York City, New York
Listed
Feb 8, 2021
Sector
Health Care
Industry
Biotechnology
Website
brightmindsbio.com

DRUG key statistics

Market cap
728.43M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
162.22K
Volume
59.20K
Open price
$51.77
High today
$52.65
Low today
$51.00
52 Week high
$123.75
52 Week low
$47.23

Bright Minds Biosciences (DRUG) at a glance

As of Oct 23, 2026, Bright Minds Biosciences (DRUG) shares are priced at $52.48, giving the company a market cap of 728.43M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $51.00 and $52.65. The current price is 2.9% above the day's low and 0.3% below its high.

Volume so far is 59.20K shares, below the average of 162.22K shares a day.

Over the past year Bright Minds Biosciences has ranged from $47.23 to $123.75, and now sits 7% of the way up that range.

The average analyst price target is $8.80, 83.2% below the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $8.80
Low
$8.71
Now
$52.48
High
$9.06

DRUG news

  • Press releaseGlobe Newswire

    Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

  • Press releaseGlobe Newswire

    Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

  • 'Trump To Sign Executive Order On Psychedelic Drug Used Abroad To Treat PTSD' - CBS News Exclusive

  • Press releaseGlobe Newswire

    Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

  • Press releaseGlobe Newswire

    Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

  • Avi Kapoor

    Crude Oil Down 2%; ISM Services PMI Surges In December

  • Press releaseGlobe Newswire

    Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

  • Press releaseGlobe Newswire

    Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Similar companies

Companies in the same industry as Bright Minds Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.